BioCentury
ARTICLE | Finance

Spring cleaning

SpringWorks provides a development path for pharma's de-prioritized assets

September 29, 2017 9:00 PM UTC

SpringWorks Therapeutics LLC aims to partner with pharmas and big biotechs seeking a development path for clinical stage assets outside of their core therapeutic areas. With its tranched $103 million series A round, the newco will advance existing programs spun out of Pfizer Inc. (NYSE:PFE) while it continues to expand its pipeline.

Bain Capital Life Sciences, Bain Capital Double Impact and OrbiMed led the tranched round, joined by Pfizer and LifeArc. Details regarding the tranches are not disclosed. ...